Solid biosciences provides third quarter 2022 business update and financial results

- recently presented preclinical data support potential benefits of next-generation duchenne gene therapy candidate sgt-003; program on track for mid-2023 investigational new drug (ind) submission -
SLDB Ratings Summary
SLDB Quant Ranking